- Home
- WPP vs HALO Comparison
WPP vs HALO Comparison
Compare WPP & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | HALO |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 8.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WPP | HALO |
|---|---|---|
| Price | $20.66 | $70.35 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 12 |
| Target Price | N/A | ★ $76.42 |
| AVG Volume (30 Days) | 475.5K | ★ 1.7M |
| Earning Date | 02-26-2026 | 02-17-2026 |
| Dividend Yield | ★ 10.27% | N/A |
| EPS Growth | ★ 86.47 | 56.68 |
| EPS | 0.47 | ★ 4.74 |
| Revenue | ★ $19,423,208,660.00 | $1,242,852,000.00 |
| Revenue This Year | N/A | $34.54 |
| Revenue Next Year | N/A | $26.28 |
| P/E Ratio | $43.45 | ★ $14.87 |
| Revenue Growth | N/A | ★ 31.19 |
| 52 Week Low | $17.47 | $47.50 |
| 52 Week High | $49.12 | $79.50 |
Technical Indicators
Market Signals| Indicator | WPP | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 52.04 |
| Support Level | $21.50 | $70.75 |
| Resistance Level | $23.79 | $74.08 |
| Average True Range (ATR) | 0.69 | 2.07 |
| MACD | -0.31 | -0.07 |
| Stochastic Oscillator | 3.08 | 40.32 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.